Paraoxonase 1 and Arylesterase Levels in Patients with Ulcerative Colitis and Their Relationships with the Disease Activity

Background and Aims: In this study, we studied serum paraoxanase 1 and arylesterase levels in patients with ulcerative colitis and their relationship with disease activity. Material and Methods: Thirty-eight patients with active ulcerative colitis and 38 healthy controls were included in this study. Paraoxanase 1 and arylesterase enzyme activities in both active and remission phases were studied. Paraoxanase 1 and arylesterase enzyme activities in the active disease phase, the remission phase, and the control group were compared. Results: The mean patient age in the study group was 40.3±14.6 years (19-78); 20 patients were male (52.6%) and 18 were female (47.4%). The demographic characteristics of the patients in the control group were similar to those of the study group. The mean serum paraoxanase 1 level was 65.8±15.0 U/L, and the mean serum arylesterase level was 151.0±236.6 U/mL in patients in the active phase. The mean serum paraoxanase 1 level was 82.4±58.4 U/L, and the mean serum arylesterase level was 94.1±134.6 U/mL in patients in the remission phase. The mean serum paraoxanase 1 level was 131.7±63.5 U/L, and the mean serum arylesterase level was 287.3±295.6 U/mL in the control group. There was no statistically significant difference in mean paraoxanase 1 and arylesterase levels between patients in the active and remission phases (p > 0.05). The mean levels of paraoxanase 1 and arylesterase in patients in the active and remission phases were significantly lower than those in healthy controls (p < 0.05). Conclusion: In patients with ulcerative colitis, paraoxanase 1 and arylesterase enzyme activities were found to be significantly lower than those in the control group, but there was no relationship between disease activity and paraoxanase 1 and arylesterase enzyme activities